Research programme: drug discovery - MedImmune/Philochem AG
Latest Information Update: 26 Aug 2010
At a glance
- Originator Cambridge Antibody Technology; Philochem
- Developer MedImmune
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 29 Oct 2007 Cambridge Antibody Technology has been integrated into MedImmune
- 19 Apr 2007 Preclinical trials in Undefined indication in Europe (unspecified route)